Source:http://linkedlifedata.com/resource/pubmed/id/10396316
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
7
|
| pubmed:dateCreated |
1999-7-15
|
| pubmed:abstractText |
The combination Phase I study of gemcitabine hydrochloride with cisplatin was conducted in the patients with non-small cell lung cancer (NSCLC) at 5 investigation sites. Gemcitabine was administrated on day 1, 8 and 15 and cisplatin on day 1 of each 28-day cycle. The dosage of cisplatin was fixed to 80 mg/m2 and the dosage of Gemcitabine was gradually escalated in 3 dosing level from 600, 800 to 1,000 mg/m2. The maximum tolerated dose (MTD) and the recommended dose was determined with Continual Reassessment Method. For each dose level, 6 cases, 3 cases and 6 cases were registered respectively and all 15 cases were evaluable. In the dose level 3 with 1,000 mg/m2 of gemcitabine and 80 mg/m2 of cisplatin, grade 4 neutropenia was observed as DLT in 3 out of 6 cases, thus dose level 3 was considered as MTD and the recommended dose. Major adverse events were leukopenia, neutropenia, nausea/vomiting and anorexia. The incidence of such adverse events seemed to be dose-dependent and especially the grade of neutropenia seemed to be more serious as the dose increased. Also, the grade of liver function tests abnormal seemed to be more serious as the dose increased but the incidence as well as the grade did not have tendency of dose-dependent in another events including renal function tests abnormal. On the other hand, as to the efficacy PR was observed in 4 out of 15 cases. Based upon the results, it is necessary to discuss further the efficacy in the recommended dose in the combination therapy of gemcitabine and cisplatin.
|
| pubmed:language |
jpn
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0385-0684
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
26
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
898-907
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:10396316-Adenocarcinoma,
pubmed-meshheading:10396316-Adult,
pubmed-meshheading:10396316-Aged,
pubmed-meshheading:10396316-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10396316-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:10396316-Carcinoma, Squamous Cell,
pubmed-meshheading:10396316-Cisplatin,
pubmed-meshheading:10396316-Deoxycytidine,
pubmed-meshheading:10396316-Drug Administration Schedule,
pubmed-meshheading:10396316-Drug Evaluation,
pubmed-meshheading:10396316-Female,
pubmed-meshheading:10396316-Humans,
pubmed-meshheading:10396316-Leukopenia,
pubmed-meshheading:10396316-Lung Neoplasms,
pubmed-meshheading:10396316-Male,
pubmed-meshheading:10396316-Middle Aged,
pubmed-meshheading:10396316-Nausea,
pubmed-meshheading:10396316-Neutropenia,
pubmed-meshheading:10396316-Vomiting, Anticipatory
|
| pubmed:year |
1999
|
| pubmed:articleTitle |
[Phase I study of gemcitabine hydrochloride (LY 188011) combination therapy with cisplatin in the patients with non-small cell lung cancer].
|
| pubmed:affiliation |
Department of Internal Medicine, Niigata Cancer Center Hospital, Japan.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
English Abstract,
Multicenter Study,
Clinical Trial, Phase I
|